Ra Capital Management, L.P. Gh Research PLC Transaction History

Ra Capital Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$5.34 - $11.09 $3.55 Million - $7.37 Million	664,381 Added 11.89%	6,251,714 $66.6 Million
Q4 2023 Feb 14, 2024	BUY	$5.26 - $11.04 $29.4 Million - $61.7 Million	5,587,333 New	5,587,333 $32.4 Million
Q2 2023 Aug 14, 2023	BUY	$7.88 - $12.74 $48,635 - $78,631	6,172 Added 0.11%	5,587,333 $66.3 Million
Q1 2023 May 15, 2023	BUY	$6.02 - $10.92 $4.11 Million - $7.46 Million	682,788 Added 13.94%	5,581,161 $44.6 Million
Q2 2022 Aug 15, 2022	BUY	$8.99 - $19.87 $638,676 - $1.41 Million	71,043 Added 1.47%	4,898,373 $48.9 Million

Q1 2022 May 16, 2022	BUY	$15.48 - $23.98 $30.7 Million - $47.6 Million	1,983,573 Added 69.75%	4,827,330 $88.3 Million
Q4 2021 Feb 14, 2022	SELL	$14.1 - $27.9 $2.4 Million - $4.75 Million	-170,200 Reduced 5.65%	2,843,757 $66.3 Million
Q3 2021 Nov 15, 2021	BUY	$16.51 - $23.68 $577,883 - $828,847	35,002 Added 1.17%	3,013,957 $66.5 Million
Q2 2021 Aug 16, 2021	BUY	$19.25 - $21.73 $57.3 Million - $64.7 Million	2,978,955 New	2,978,955 $64.7 Million

17M

25.5K

19.8K

Ticker GHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,020,800
Market Cap $588M
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.